Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Perspective Therapeutics (CATX) over the last 9 years, with Q3 2025 value amounting to $48.2 million.

  • Perspective Therapeutics' Change in Acquisitions & Divestments changed N/A to $48.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.2 million, marking a year-over-year increase of 31904.25%. This contributed to the annual value of $78.7 million for FY2024, which is 24585.31% up from last year.
  • Per Perspective Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $48.2 million for Q3 2025.
  • In the past 5 years, Perspective Therapeutics' Change in Acquisitions & Divestments registered a high of $49.8 million during Q2 2025, and its lowest value of $12.5 million during Q4 2022.
  • In the last 4 years, Perspective Therapeutics' Change in Acquisitions & Divestments had a median value of $38.2 million in 2024 and averaged $33.4 million.
  • Data for Perspective Therapeutics' Change in Acquisitions & Divestments shows a peak YoY increase of 3032.31% (in 2025) and a maximum YoY decrease of 3032.31% (in 2025) over the last 5 years.
  • Perspective Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $12.5 million in 2022, then surged by 81.56% to $22.8 million in 2023, then soared by 77.93% to $40.5 million in 2024, then grew by 18.88% to $48.2 million in 2025.
  • Its Change in Acquisitions & Divestments was $48.2 million in Q3 2025, compared to $49.8 million in Q2 2025 and $21.7 million in Q1 2025.